← back to search

Nicole Pratt

University of Manitoba · CA
Area of research
Toxicology · Geriatrics and Gerontology
Research interest
Research interests include Medicine, Internal medicine, Population, Coronavirus disease 2019 (COVID-19), First line, and Observational study.
h-index
citations
2,118
works
17
NIH funding
primary concept
email

Recent publications

Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study
Age and Ageing 2025cited by 10position: middledoi
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Journal of the American College of Cardiology 2024cited by 30position: middledoi
Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study
The Lancet Regional Health - Western Pacific 2023cited by 36position: middledoi
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM
BMJ Medicine 2023cited by 26position: middledoi
Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease‐modifying antirheumatic drugs: A multi‐centre cohort study
Journal of Internal Medicine 2023cited by 24position: middledoi
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty
JAMA 2022cited by 174position: middledoi
Estimating incidence rates of periprosthetic joint infection after hip and knee arthroplasty for osteoarthritis using linked registry and administrative health data
The Bone & Joint Journal 2022cited by 105position: middledoi
Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network
BMC Medical Research Methodology 2022cited by 33position: middledoi
Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study
Hypertension 2021cited by 177position: middledoi
Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients
Hypertension 2021cited by 42position: middledoi
Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension
JAMA Internal Medicine 2020cited by 139position: middledoi
Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
The Lancet Digital Health 2020cited by 128position: middledoi
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
The Lancet 2019cited by 379position: middledoi
Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases
The Lancet Psychiatry 2018cited by 305position: middledoi
Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies
European Journal of Epidemiology 2017cited by 87position: middledoi
Characterizing treatment pathways at scale using the OHDSI network
Proceedings of the National Academy of Sciences 2016cited by 347position: middledoi
The Asian Pharmacoepidemiology Network (AsPEN): promoting multi‐national collaboration for pharmacoepidemiologic research in Asia
Pharmacoepidemiology and Drug Safety 2013cited by 76position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Patrick Ryan · Columbia University5 papers (2016–2021)Martijn J. Schuemie · Johnson & Johnson (United States)5 papers (2016–2021)David Madigan · Columbia University5 papers (2016–2021)Marc A. Suchard · Charles R. Drew University of Medicine and Science5 papers (2016–2021)George Hripcsak · Columbia University Irving Medical Center5 papers (2016–2021) · 4 papers (2019–2021)Jon Duke · Georgia Institute of Technology4 papers (2016–2021)Harlan M. Krumholz · Yale University4 papers (2019–2021)Ruijun Chen · Tempus Labs (United States)4 papers (2019–2021)Christian Reich · World Vision4 papers (2016–2021)Steven Shea · New York Hospital Queens3 papers (2020–2021)Edward Chia‐Cheng Lai · Weill Cornell Medicine3 papers (2013–2023) · 2 papers (2013–2017) · 2 papers (2016–2021)Ian Chi Kei Wong · Advanced Materials Enterprises (China)2 papers (2023–2025) · 2 papers (2023–2025)Ju‐Young Shin · Yonsei University Health System2 papers (2013–2023)Elizabeth E. Roughead · Flinders University2 papers (2013–2017)Yogini Jani · University of London1 papers (2025–2025)Jessica J. Jalbert · Regeneron (United States)1 papers (2013–2013)